Search research articles
Contact Us
Filters
Showing results (71-80 of 88) with videos related to
Page
of 9
Sort By:
Frontiers in Oncology
|
February 9, 2026
Personalized tumor-informed circulating tumor DNA monitoring for early detection of recurrence in postoperative pancreatic cancer
Jingjing Chen, Lu Zou, Xinyuan Bai, et al.
Scientific Reports
|
January 20, 2019
Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC
Ling Wu, Fanyan Meng, Lun Dong, et al.
American Journal of Cancer Research
|
February 9, 2018
Bispecific tumor-penetrating protein anti-EGFR-iRGD efficiently enhances the infiltration of lymphocytes in gastric cancer
Anqing Zhu, Huizi Sha, Shu Su, et al.
Nature Communications
|
December 3, 2022
Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy
Junmeng Zhu, Yaohua Ke, Qin Liu, et al.
Nature Communications
|
March 24, 2019
iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
Naiqing Ding, Zhengyun Zou, Huizi Sha, et al.
Journal of Nanobiotechnology
|
February 19, 2025
Enzymatically responsive nanocarriers targeting PD-1 and TGF-β pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy
Ying-Tzu Yen, Zhifan Zhang, Anni Chen, et al.
European Journal of Medical Research
|
August 25, 2025
Exploring the impact of high rosuvastatin plasma exposure on new-onset diabetes mellitus: insights from machine learning-based prediction
Yu Chen, Fanyan Meng, Fang Song, et al.
Oncoimmunology
|
February 16, 2017
CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer
Shu Su, Zhengyun Zou, Fangjun Chen, et al.
Scientific Reports
|
January 20, 2017
Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Shu Su, Bian Hu, Jie Shao, et al.
Scientific Reports
|
January 29, 2016
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Shu Su, Bian Hu, Jie Shao, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 88) with videos related to
Sort By:
Page
of 9
Frontiers in Oncology
|
February 9, 2026
Personalized tumor-informed circulating tumor DNA monitoring for early detection of recurrence in postoperative pancreatic cancer
Jingjing Chen, Lu Zou, Xinyuan Bai, et al.
Scientific Reports
|
January 20, 2019
Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC
Ling Wu, Fanyan Meng, Lun Dong, et al.
American Journal of Cancer Research
|
February 9, 2018
Bispecific tumor-penetrating protein anti-EGFR-iRGD efficiently enhances the infiltration of lymphocytes in gastric cancer
Anqing Zhu, Huizi Sha, Shu Su, et al.
Nature Communications
|
December 3, 2022
Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy
Junmeng Zhu, Yaohua Ke, Qin Liu, et al.
Nature Communications
|
March 24, 2019
iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
Naiqing Ding, Zhengyun Zou, Huizi Sha, et al.
Journal of Nanobiotechnology
|
February 19, 2025
Enzymatically responsive nanocarriers targeting PD-1 and TGF-β pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy
Ying-Tzu Yen, Zhifan Zhang, Anni Chen, et al.
European Journal of Medical Research
|
August 25, 2025
Exploring the impact of high rosuvastatin plasma exposure on new-onset diabetes mellitus: insights from machine learning-based prediction
Yu Chen, Fanyan Meng, Fang Song, et al.
Oncoimmunology
|
February 16, 2017
CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer
Shu Su, Zhengyun Zou, Fangjun Chen, et al.
Scientific Reports
|
January 20, 2017
Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Shu Su, Bian Hu, Jie Shao, et al.
Scientific Reports
|
January 29, 2016
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Shu Su, Bian Hu, Jie Shao, et al.
Page
of 9